Spots Global Cancer Trial Database for navitoclax
Every month we try and update this database with for navitoclax cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | NCT00406809 | Chronic Lymphoi... Lymphoid Malign... Non-Hodgkin's L... Follicular Lymp... Mantle Cell Lym... Peripheral T-ce... | ABT-263 | 18 Years - 99 Years | AbbVie | |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | NCT06210750 | T Acute Lymphob... T Lymphoblastic... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Calaspargase Pe... Computed Tomogr... Cyclophosphamid... Cytarabine Daunorubicin Dexamethasone Doxorubicin Echocardiograph... Lumbar Puncture Mercaptopurine Methotrexate Multigated Acqu... Navitoclax Nelarabine Pegaspargase Positron Emissi... Thioguanine Venetoclax Vincristine X-Ray Imaging | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04454658 | Myelofibrosis (... | ABBV-744 Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| Expanded Access to Navitoclax | NCT03592576 | Myelofibrosis Acute Lymphocyt... Lymphoblastic L... | Navitoclax Venetoclax | 4 Years - | AbbVie | |
| Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) | NCT01557777 | Chronic Lymphoc... | Navitoclax | 18 Years - | AbbVie | |
| Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | NCT01989585 | Clinical Stage ... Clinical Stage ... Malignant Solid... Metastatic Mela... Unresectable Me... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Navitoclax Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | NCT02079740 | Metastatic Mali... Refractory Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre | |
| Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer | NCT02520778 | Advanced Lung N... Metastatic Lung... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung N... | Navitoclax Osimertinib | 18 Years - | National Cancer Institute (NCI) | |
| Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | NCT05222984 | Recurrent Acute... Refractory Acut... | Decitabine Navitoclax Venetoclax | 16 Years - | City of Hope Medical Center | |
| Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre | |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | NCT02143401 | Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So... | Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) | NCT01423539 | Diffuse Large B... | bendamustine navitoclax rituximab | 18 Years - | Genentech, Inc. | |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | NCT02143401 | Cirrhosis Hepatitis B Inf... Hepatitis C Inf... Metastatic Mali... Recurrent Hepat... Recurrent Malig... Refractory Mali... Stage IV Hepato... Unresectable So... | Laboratory Biom... Navitoclax Pharmacological... Sorafenib Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome | NCT05564650 | Myelodysplastic... Recurrent Myelo... Refractory Myel... | Navitoclax Venetoclax Decitabine Bone Marrow Bio... Biospecimen Col... Laboratory Biom... Quality-of-Life... | 18 Years - | Thomas Jefferson University | |
| Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | NCT04472598 | Myelofibrosis (... | Navitoclax Ruxolitinib Placebo for Nav... | 18 Years - | AbbVie | |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | NCT02079740 | Metastatic Mali... Refractory Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | NCT06007911 | Relapsed Adult ... Refractory AML | Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Navitoclax Dose... Venetoclax Dose... Venetoclax Dose... Cladribine Cytarabine (Cla... Cytarabine (CLA... Mitoxantrone Granulocyte Col... | 18 Years - | Medical College of Wisconsin | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04480086 | Myelofibrosis (... | Mivebresib Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome | NCT05564650 | Myelodysplastic... Recurrent Myelo... Refractory Myel... | Navitoclax Venetoclax Decitabine Bone Marrow Bio... Biospecimen Col... Laboratory Biom... Quality-of-Life... | 18 Years - | Thomas Jefferson University | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma | NCT03181126 | Acute Lymphobla... Lymphoblastic L... | Navitoclax Chemotherapy Venetoclax | 4 Years - | AbbVie | |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | NCT02079740 | Metastatic Mali... Refractory Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | NCT03366103 | Metastatic Mali... Recurrent Lung ... Recurrent Malig... Refractory Mali... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung S... Unresectable So... | Navitoclax Vistusertib | 18 Years - | National Cancer Institute (NCI) | |
| Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL | NCT05215405 | Relapsed Childh... Relapsed Childh... | Venetoclax Navitoclax | 4 Years - | University of Texas Southwestern Medical Center | |
| Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors | NCT03366103 | Metastatic Mali... Recurrent Lung ... Recurrent Malig... Refractory Mali... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IV Lung S... Unresectable So... | Navitoclax Vistusertib | 18 Years - | National Cancer Institute (NCI) | |
| Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | NCT05864742 | Mantle Cell Lym... | Ibrutinib Venetoclax Navitoclax Rituximab | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | NCT05455294 | Myeloid Maligna... Myelodysplastic... Myelofibrosis Acute Myeloid L... Myeloproliferat... | Navitoclax Venetoclax Decitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04480086 | Myelofibrosis (... | Mivebresib Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | NCT05192889 | Refractory Acut... Relapsed Acute ... | Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation | 4 Years - 30 Years | St. Jude Children's Research Hospital | |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | NCT05192889 | Refractory Acut... Relapsed Acute ... | Venetoclax Navitoclax Dexamethasone Vincristine Calaspargase Pe... Dasatinib Cytarabine Blinatumomab Methotrexate Mercaptopurine Cyclophosphamid... Etoposide Leucovorin Intrathecal Tri... Pegaspargase Erwinia asparag... Radiation | 4 Years - 30 Years | St. Jude Children's Research Hospital | |
| A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL | NCT05054465 | Acute Lymphobla... | Navitoclax Venetoclax | 18 Years - | Israeli Medical Association | |
| A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE) | NCT01423539 | Diffuse Large B... | bendamustine navitoclax rituximab | 18 Years - | Genentech, Inc. | |
| Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | NCT05358639 | High Grade Sero... Triple Negative... Ovarian Cancer | Olaparib tablet Navitoclax | 18 Years - | Sunnybrook Health Sciences Centre |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
